Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 205

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1A
Chunk 205
---
 in placement agent fees, October 2024 offering and the $790 thousand senior secured convertible
note offering, along with our existing capital resources, will not be sufficient to fund our operations one year after the date that
the consolidated financial statements are issued without additional capital infusion. We anticipate we will need to seek additional
funding through public or private equity or debt financings or other sources, such as through a rights offering, strategic
collaborations or grants and contracts. Such financing may result in dilution to stockholders, imposition of debt covenants and
repayment obligations, or other restrictions that may adversely affect our business. In addition, we may seek additional capital due
to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future
operating plans.

25

Our
future capital requirements depend on many factors, including:

    ●
    the
    scope, progress, results and costs of researching and developing our current product candidates, future product candidates and conducting
    preclinical and clinical trials;

    ●
    the
    cost of commercialization activities if our current product candidates and future product candidates are approved for sale, including
    securing collaborative ventures for completing development of, securing marketing approval for and ultimately marketing, selling
    and distributing our product candidates, if approved or building a corporate infrastructure if we have to undertake these activities
    directly;

    ●
    our
    ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such agreements;

    ●
    the
    number and characteristics of any additional product candidates we may develop or acquire;

    ●
    any
    product liability or other lawsuits related to our products or commenced against us;

    ●
    the
    expenses needed to attract and retain skilled personnel;

    ●
    the
    costs associated with being a public company;

    ●
    the
    costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs
    and the outcome of such litigation; and

    ●
    the
    timing, receipt and amount of sales of, or royalties on, any future approved products, if any.

Additional
funds may not be available when we need them, on terms that are acceptable to us, or at all. If adequate funds are not available to us
on a timely basis, we may be required to:

    ●
    delay,
    limit, reduce or terminate preclinical studies